{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:57Z","timestamp":1792782897120,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Science, Technology & Innovation Funding Authority"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune thrombocytopenic purpura (ITP) is a challenging disease in its presentation and management as it may cause life-threatening hemorrhaging in vital organs and may resist several lines of treatment. This systematic review and meta-analysis aimed to evaluate the safety and efficacy of mycophenolate mofetil (MMF) in treating patients with ITP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched four electronic databases (PubMed, Scopus,\u00a0Web of Science, and Cochrane Central Register of Controlled Trials) from inception until 10 October 2022. We included all clinical trials, either controlled or single arm, and prospective and retrospective observational studies that evaluate the efficacy and safety of MMF in patients with ITP. We assessed the risk of bias using three tools (ROBINS-I, Cochrane ROB-2, and NIH), each for eligible study design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine studies were included in this meta-analysis, with a total of 411 patients with ITP. We found that MMF demonstrated an overall response rate of (62.09%; 95% CI\u2009=\u2009[43.29 to 77.84]) and the complete response rate was (46.75%; 95% CI\u2009=\u2009[24.84 to 69.99]). The overall proportion of adverse events was (12%; 95% CI\u2009=\u2009[6 to 24]). After the sensitivity analysis, the overall response rate became 50%; 95% CI\u2009=\u2009[38 to 63]) and the complete response rate became (32%; 95% CI\u2009=\u2009[24 to 42]). However, MMF did not appear to affect white blood cell counts or hemoglobin levels significantly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This systematic review and meta-analysis demonstrate that MMF appears to be an effective and relatively safe treatment option for patients with ITP when combined with steroids and even in those who have not responded to standard therapies (steroid-resistant cases). Further research with well-designed studies is warranted to better understand the factors influencing treatment response and to refine the use of MMF in the management of ITP. An interactive version of our analysis can be accessed from here:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/databoard.shinyapps.io\/mycophenolate_meta\/\">https:\/\/databoard.shinyapps.io\/mycophenolate_meta\/<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-023-06820-4","type":"journal-article","created":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T22:02:11Z","timestamp":1700431331000},"page":"621-632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8266-0245","authenticated-orcid":false,"given":"Omar Ahmed","family":"Abdelwahab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4682-1392","authenticated-orcid":false,"given":"Ahmed","family":"Mechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Gahlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima-Elzahraa","family":"Hamadein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallas","family":"Kadhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0203-4008","authenticated-orcid":false,"given":"Doaa","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El\u2011Samahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"issue":"13","key":"6820_CR1","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMRA010501","volume":"346","author":"DB Cines","year":"2002","unstructured":"Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Engl J Med 346(13):995\u20131008. https:\/\/doi.org\/10.1056\/NEJMRA010501","journal-title":"N Engl J Med"},{"issue":"2","key":"6820_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10555-017-9677-x","volume":"36","author":"M Holinstat","year":"2017","unstructured":"Holinstat M (2017) Normal platelet function. Cancer Metastasis Rev 36(2):195\u2013198. https:\/\/doi.org\/10.1007\/s10555-017-9677-x","journal-title":"Cancer Metastasis Rev"},{"key":"6820_CR3","doi-asserted-by":"publisher","unstructured":"Miyata S (2012) Recent advances in the pathogenesis, diagnosis, and treatment of immune heparin-induced thrombocytopenia. Japan J Thromb Hemost 23.\u00a0https:\/\/doi.org\/10.2491\/jjsth.23.362","DOI":"10.2491\/jjsth.23.362"},{"key":"6820_CR4","doi-asserted-by":"publisher","unstructured":"Audia S, Mahevas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B (2021) Immune thrombocytopenia: recent advances in pathogenesis and treatments. Hemasphere 5. https:\/\/doi.org\/10.1097\/HS9.0000000000000574","DOI":"10.1097\/HS9.0000000000000574"},{"issue":"1","key":"6820_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1634\/theoncologist.2008-0132","volume":"14","author":"T Gernsheimer","year":"2009","unstructured":"Gernsheimer T (2009) Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist 14(1):12. https:\/\/doi.org\/10.1634\/theoncologist.2008-0132","journal-title":"Oncologist"},{"issue":"1","key":"6820_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/asheducation-2018.1.405","volume":"2018","author":"JM Despotovic","year":"2018","unstructured":"Despotovic JM, Grimes AB (2018) Pediatric ITP: is it different from adult ITP? Hematol (United States) 2018(1):405. https:\/\/doi.org\/10.1182\/asheducation-2018.1.405","journal-title":"Hematol (United States)"},{"issue":"1","key":"6820_CR7","first-page":"27","volume":"12","author":"ME Faki Osman","year":"2012","unstructured":"Faki Osman ME (2012) Childhood immune thrombocytopenia: clinical presentation and management. Sudan J Paediatr 12(1):27\u201339","journal-title":"Sudan J Paediatr"},{"issue":"3","key":"6820_CR8","first-page":"30","volume":"8","author":"S Saeidi","year":"2014","unstructured":"Saeidi S, Jaseb K, Asnafi AA, Rahim F, Pourmotahari F, Mardaniyan S, Yousefi H, Alghasi A, Shahjahani M, Saki N (2014) Immune thrombocytopenic purpura in children and adults: a comparative retrospective study in IRAN. Int J Hematol Oncol Stem Cell Res 8(3):30\u20136","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"21","key":"6820_CR9","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","volume":"129","author":"MP Lambert","year":"2017","unstructured":"Lambert MP, Gernsheimer TB (2017) Clinical updates in adult immune thrombocytopenia. Blood 129(21):2829\u20132835. https:\/\/doi.org\/10.1182\/blood-2017-03-754119","journal-title":"Blood"},{"key":"6820_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/OAEM.S331675","volume":"14","author":"T Zitek","year":"2022","unstructured":"Zitek T, Weber L, Pinzon D, Warren N (2022) Assessment and management of immune thrombocytopenia (ITP) in the emergency department: current perspectives. Open Access Emerg Med 14:25\u201334. https:\/\/doi.org\/10.2147\/OAEM.S331675","journal-title":"Open Access Emerg Med"},{"issue":"2","key":"6820_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm6020016","volume":"6","author":"A Zufferey","year":"2017","unstructured":"Zufferey A, Kapur R, Semple JW (2017) Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med 6(2):16. https:\/\/doi.org\/10.3390\/jcm6020016","journal-title":"J Clin Med"},{"key":"6820_CR12","doi-asserted-by":"publisher","unstructured":"Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, Jansen AJG (2018) Emerging concepts in immune thrombocytopenia. Front Immunol 9.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2018.00880","DOI":"10.3389\/fimmu.2018.00880"},{"issue":"5","key":"6820_CR13","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/jcm10051004","volume":"10","author":"S Audia","year":"2021","unstructured":"Audia S, Bonnotte B (2021) Emerging therapies in immune thrombocytopenia. J Clin Med 10(5):1004. https:\/\/doi.org\/10.3390\/jcm10051004","journal-title":"J Clin Med"},{"key":"6820_CR14","doi-asserted-by":"publisher","unstructured":"Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, et al. (2013) Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood 121. https:\/\/doi.org\/10.1182\/blood-2012-07-442392","DOI":"10.1182\/blood-2012-07-442392"},{"key":"6820_CR15","doi-asserted-by":"publisher","unstructured":"Cuker A, Liebman HA (2021) Corticosteroid overuse in adults with immune thrombocytopenia: cause for concern. Res Pract Thromb Haemost 5.\u00a0\u00a0https:\/\/doi.org\/10.1002\/rth2.12592","DOI":"10.1002\/rth2.12592"},{"key":"6820_CR16","doi-asserted-by":"publisher","unstructured":"Almizraq RJ, Branch DR (2021) Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults. Ann Blood 6.\u00a0https:\/\/doi.org\/10.21037\/aob-20-87","DOI":"10.21037\/aob-20-87"},{"key":"6820_CR17","doi-asserted-by":"publisher","unstructured":"Cheung E, Liebman HA (2009) Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biol 3.\u00a0https:\/\/doi.org\/10.2147\/btt.s3166","DOI":"10.2147\/btt.s3166"},{"issue":"10","key":"6820_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/nejmoa2100596","volume":"385","author":"CA Bradbury","year":"2021","unstructured":"Bradbury CA, Pell J, Hill Q, Bagot C, Cooper N, Ingram J et al (2021) Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England J Med 385(10):885\u2013895. https:\/\/doi.org\/10.1056\/nejmoa2100596","journal-title":"New England J Med"},{"issue":"6","key":"6820_CR19","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","volume":"104","author":"E Lucchini","year":"2019","unstructured":"Lucchini E, Zaja F, Bussel J (2019) Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica 104(6):1124\u20131135. https:\/\/doi.org\/10.3324\/haematol.2019.218883","journal-title":"Haematologica"},{"key":"6820_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5923\/j.ijim.20150401.03","volume":"2015","author":"MN Al-Alfy","year":"2015","unstructured":"Al-Alfy MN, Hamdy A (2015) Methotrexate as a promising treatment for immune thrombocytopenia. Int J Intern Med 2015:14\u201316. https:\/\/doi.org\/10.5923\/j.ijim.20150401.03","journal-title":"Int J Intern Med"},{"key":"6820_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.imlet.2023.01.008","volume":"254","author":"OA Abdelwahab","year":"2023","unstructured":"Abdelwahab OA, Seif AM, Sherif MES (2023) Why should we consider methotrexate in future trials of steroid-resistant immune thrombocytopenic purpura? Correspondence. Immunol Lett 254:39\u201340. https:\/\/doi.org\/10.1016\/j.imlet.2023.01.008","journal-title":"Immunol Lett"},{"key":"6820_CR22","doi-asserted-by":"publisher","unstructured":"Kojouri K, Vesely SK, Terrell DR, George JN (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104.\u00a0\u00a0https:\/\/doi.org\/10.1182\/blood-2004-03-1168","DOI":"10.1182\/blood-2004-03-1168"},{"issue":"2\u20133","key":"6820_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacol 47(2\u20133):85\u2013118. https:\/\/doi.org\/10.1016\/S0162-3109(00)00188-0","journal-title":"Immunopharmacol"},{"issue":"9","key":"6820_CR24","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/cancers11091346","volume":"11","author":"R Naffouje","year":"2019","unstructured":"Naffouje R, Grover P, Yu H, Sendilnathan A, Wolfe K, Majd N et al (2019) Anti-tumor potential of IMP dehydrogenase inhibitors: a century-long story. Cancers (Basel) 11(9):1346. https:\/\/doi.org\/10.3390\/cancers11091346","journal-title":"Cancers (Basel)"},{"key":"6820_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1042\/CS20030331","volume":"107","author":"D Goldsmith","year":"2004","unstructured":"Goldsmith D, Carrey EA, Edbury S, Smolenski RT, Jagodzinski P, Simmonds HA (2004) Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci 107:63\u201368. https:\/\/doi.org\/10.1042\/CS20030331","journal-title":"Clin Sci"},{"issue":"3","key":"6820_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.autrev.2006.11.001","volume":"6","author":"L Iaccarino","year":"2007","unstructured":"Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A (2007) Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 6(3):190\u2013195. https:\/\/doi.org\/10.1016\/j.autrev.2006.11.001","journal-title":"Autoimmun Rev"},{"issue":"4","key":"6820_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bjh.13622","volume":"171","author":"A Taylor","year":"2015","unstructured":"Taylor A, Neave L, Solanki S, Westwood JP, Terrinonive I, Mcguckin S et al (2015) Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol 171(4):625\u2013630. https:\/\/doi.org\/10.1111\/bjh.13622","journal-title":"Br J Haematol"},{"key":"6820_CR28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/bmj.n71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. The BMJ 2021:372. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"The BMJ"},{"key":"6820_CR29","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al (2021) Cochrane handbook for systematic reviews of interventions version 6.2 [updated February 2021]. Cochrane. Available from www.training.cochrane.org\/handbook"},{"key":"6820_CR30","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Online) 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ (Online)"},{"key":"6820_CR31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. The BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"The BMJ"},{"key":"6820_CR32","unstructured":"NIH (2014) Quality assessment tool for before-after (pre-post) studies with no control group. https:\/\/www.NhlbiNih.Gov\/Health-Topics\/Study-Quality-Assessment-Tools.\u00a0Accessed 16 Aug 2023"},{"issue":"7109","key":"6820_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"Br Med J"},{"issue":"13","key":"6820_CR34","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/sim.1461","volume":"22","author":"N Terrin","year":"2003","unstructured":"Terrin N, Schmid CH, Lau J, Olkin I (2003) Adjusting for publication bias in the presence of heterogeneity.[erratum appears in Stat Med. 2005 Mar 15;24(5):825-6]. Stat Med 22(13):2113\u20132126. https:\/\/doi.org\/10.1002\/sim.1461","journal-title":"Stat Med"},{"issue":"6","key":"6820_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1034\/j.1600-0609.2003.00076.x","volume":"70","author":"M Hou","year":"2003","unstructured":"Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C et al (2003) Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol 70(6):353\u2013357. https:\/\/doi.org\/10.1034\/j.1600-0609.2003.00076.x","journal-title":"Eur J Haematol"},{"key":"6820_CR36","doi-asserted-by":"publisher","unstructured":"\u010colovi\u0107 M, Suvajdzic N, \u010colovi\u0107 N, Tomin D, Vidovi\u0107 A, Palibrk V (2011) Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and\/or splenectomy in adults. Platelets 22. https:\/\/doi.org\/10.3109\/09537104.2010.520372","DOI":"10.3109\/09537104.2010.520372"},{"issue":"1","key":"6820_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2009-06-222448","volume":"115","author":"DM Arnold","year":"2010","unstructured":"Arnold DM, Nazi I, Santos A, Chan H, Heddle NM, Warkentin TE et al (2010) Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood 115(1):29\u201331. https:\/\/doi.org\/10.1182\/blood-2009-06-222448","journal-title":"Blood"},{"key":"6820_CR38","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/J.1745-7254.2005.00088.X","volume":"26","author":"WG Zhang","year":"2005","unstructured":"Zhang WG, Ji L, Cao XM, Chen YX, He AL, Liu J et al (2005) Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin 26:598\u2013602. https:\/\/doi.org\/10.1111\/J.1745-7254.2005.00088.X","journal-title":"Acta Pharmacol Sin"},{"key":"6820_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/AJH.20515","volume":"81","author":"D Provan","year":"2006","unstructured":"Provan D, Moss AJ, Newland AC, Bussel JB (2006) Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 81:19\u201325. https:\/\/doi.org\/10.1002\/AJH.20515","journal-title":"Am J Hematol"},{"issue":"8","key":"6820_CR40","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.sjbs.2019.09.013","volume":"26","author":"J Xu","year":"2019","unstructured":"Xu J, Wang G, Tan S, Ge Y, Liu J, Rao M et al (2019) The clinical effect of prednisone in combination with Mycophenolate mofetil on idiopathic thrombocytopenic purpura (ITP) and its influence on the level of peripheral blood T lymphocytes and NK lymphocytes. Saudi J Biol Sci 26(8):2108\u20132112. https:\/\/doi.org\/10.1016\/j.sjbs.2019.09.013","journal-title":"Saudi J Biol Sci"},{"key":"6820_CR41","doi-asserted-by":"publisher","unstructured":"Miano M, Scalzone M, Perri K, Palmisani E, Caviglia I, Micalizzi C, et al. (2015) Mycophenolate mofetil and sirolimus as second or further line treatment in children with chronic refractory primitive or secondary autoimmune cytopenias: a single centre experience. Br J Haematol 171.\u00a0https:\/\/doi.org\/10.1111\/bjh.13533","DOI":"10.1111\/bjh.13533"},{"issue":"4","key":"6820_CR42","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1093\/nar\/gkv047","volume":"43","author":"AN Lane","year":"2015","unstructured":"Lane AN, Fan TWM (2015) Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res 43(4):2466\u20132485. https:\/\/doi.org\/10.1093\/nar\/gkv047","journal-title":"Nucleic Acids Res"},{"key":"6820_CR43","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/IJGM.S298888","volume":"14","author":"X Lin","year":"2021","unstructured":"Lin X, Xu A, Zhou L, Zhao N, Zhang X, Xu J et al (2021) Imbalance of T lymphocyte subsets in adult immune thrombocytopenia. Int J Gen Med 14:937\u2013947. https:\/\/doi.org\/10.2147\/IJGM.S298888","journal-title":"Int J Gen Med"},{"issue":"7","key":"6820_CR44","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.4049\/jimmunol.1003319","volume":"187","author":"JL Karnell","year":"2011","unstructured":"Karnell JL, Karnell FG, Stephens GL, Rajan B, Morehouse C, Li Y et al (2011) Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. The J Immunol 187(7):3603\u20133612. https:\/\/doi.org\/10.4049\/jimmunol.1003319","journal-title":"The J Immunol"},{"issue":"3","key":"6820_CR45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0037-1963(00)90102-1","volume":"37","author":"R McMillan","year":"2000","unstructured":"McMillan R (2000) Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 37(3):239\u2013248. https:\/\/doi.org\/10.1016\/S0037-1963(00)90102-1","journal-title":"Semin Hematol"},{"issue":"2","key":"6820_CR46","first-page":"53","volume":"41","author":"N Aghabeigi","year":"2012","unstructured":"Aghabeigi N, Lindsey N, Zamani A, Shishaeyan B (2012) Identification and characterization of anti-platelet antibodies in idiopathic thrombocytopenic purpura patients. Iran J Public Health 41(2):53\u201362","journal-title":"Iran J Public Health"},{"issue":"4","key":"6820_CR47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/10245330701383957","volume":"12","author":"MH Meabed","year":"2007","unstructured":"Meabed MH, Taha GM, Mohamed SO, El-Hadidy KS (2007) Autoimmune thrombocytopenia: Flow cytometric determination of platelet-associated CD154\/CD40L and CD40 on peripheral blood T and B lymphocytes. Hematol 12(4):301\u2013307. https:\/\/doi.org\/10.1080\/10245330701383957","journal-title":"Hematol"},{"key":"6820_CR48","doi-asserted-by":"publisher","unstructured":"Fu L, Ma J, Cheng Z, Gu H, Ma J, Wu R ()2018) Platelet-specific antibodies and differences in their expression in childhood immune thrombocytopenic purpura predicts clinical progression. Pediatr Investig 2. https:\/\/doi.org\/10.1002\/ped4.12097","DOI":"10.1002\/ped4.12097"},{"key":"6820_CR49","doi-asserted-by":"publisher","unstructured":"Lv Y, Shi H, Liu H, Zhou L (2022) Current therapeutic strategies and perspectives in refractory ITP: what have we learned recently? Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.953716","DOI":"10.3389\/fimmu.2022.953716"},{"key":"6820_CR50","doi-asserted-by":"publisher","unstructured":"\u010coli\u0107 M, Stoji\u0107-Vukani\u0107 Z, Pavlovi\u0107 B, Jandri\u0107 D, Stefanoska I (2003) Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 134. https:\/\/doi.org\/10.1046\/j.1365-2249.2003.02269.x","DOI":"10.1046\/j.1365-2249.2003.02269.x"},{"key":"6820_CR51","doi-asserted-by":"publisher","unstructured":"Zaza G, Leventhal J, Signorini L, Gambaro G, Cravedi P (2019) Effects of antirejection drugs on innate immune cells after kidney transplantation. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.02978","DOI":"10.3389\/fimmu.2019.02978"},{"key":"6820_CR52","doi-asserted-by":"publisher","unstructured":"Katholnig K, Linke M, Pham H, Hengstschl\u00e4ger M, Weichhart T (2013) Immune responses of macrophages and dendritic cells regulated by mTOR signalling. Biochem Soc Trans 41. https:\/\/doi.org\/10.1042\/BST20130032","DOI":"10.1042\/BST20130032"},{"key":"6820_CR53","doi-asserted-by":"publisher","unstructured":"Wan YY (2010) Regulatory T cells: Immune suppression and beyond. Cell Mol Immunol 7. https:\/\/doi.org\/10.1038\/cmi.2010.20","DOI":"10.1038\/cmi.2010.20"},{"key":"6820_CR54","doi-asserted-by":"publisher","unstructured":"Corthay A (2009) How do regulatory t cells work? Scand J Immunol 70. https:\/\/doi.org\/10.1111\/j.1365-3083.2009.02308.x","DOI":"10.1111\/j.1365-3083.2009.02308.x"},{"key":"6820_CR55","doi-asserted-by":"publisher","unstructured":"Furukawa A, Wisel SA, Tang Q (2016) Impact of immune-modulatory drugs on regulatory T cell. Transplantation 100. https:\/\/doi.org\/10.1097\/TP.0000000000001379","DOI":"10.1097\/TP.0000000000001379"},{"key":"6820_CR56","doi-asserted-by":"publisher","unstructured":"Al-Hizab F, Kandeel M (2021) Mycophenolate suppresses inflammation by inhibiting prostaglandin synthases: a study of molecular and experimental drug repurposing. Peer J 9. https:\/\/doi.org\/10.7717\/peerj.11360","DOI":"10.7717\/peerj.11360"},{"key":"6820_CR57","doi-asserted-by":"publisher","unstructured":"Beduschi MG, Guimar\u00e3es CL, Buss ZS, Dalmarco EM (2013) Mycophenolate mofetil has potent anti-inflammatory actions in a mouse model of acute lung injury. Inflammation 36. https:\/\/doi.org\/10.1007\/s10753-013-9599-x","DOI":"10.1007\/s10753-013-9599-x"},{"key":"6820_CR58","doi-asserted-by":"publisher","unstructured":"Lv QK, Liu JX, Li SN, Gao YJ, Lv Y, Xu ZP, et al (2015) Article mycophenolate mofetil modulates differentiation of Th1\/Th2 and the secretion of cytokines in an active Crohn\u2019s disease mouse model. Int J Mol Sci 16. https:\/\/doi.org\/10.3390\/ijms16112598","DOI":"10.3390\/ijms16112598"},{"key":"6820_CR59","doi-asserted-by":"publisher","unstructured":"Liu Q, Liu Y (2022) Role of IL-10 and IL-22 cytokines in patients with primary immune thrombocytopenia and their clinical significance. J Clin Lab Anal 36. https:\/\/doi.org\/10.1002\/jcla.24573","DOI":"10.1002\/jcla.24573"},{"key":"6820_CR60","doi-asserted-by":"publisher","unstructured":"Goelz N, Bosch AMS, Rand ML, Eekels JJM, Franzoso FD, Schmugge M (2020) Increased levels of IL-10 and IL-1Ra counterbalance the proinflammatory cytokine pattern in acute pediatric immune thrombocytopenia. Cytokine 130. https:\/\/doi.org\/10.1016\/j.cyto.2020.155078","DOI":"10.1016\/j.cyto.2020.155078"},{"key":"6820_CR61","doi-asserted-by":"publisher","unstructured":"Zhao Y, Ni X, Xu P, Liu Q, Sun T, Liu X, et al (2020) Interleukin-37 reduces inflammation and impairs phagocytosis of platelets in immune thrombocytopenia (ITP). Cytokine 125. https:\/\/doi.org\/10.1016\/j.cyto.2019.154853","DOI":"10.1016\/j.cyto.2019.154853"},{"key":"6820_CR62","doi-asserted-by":"publisher","unstructured":"Monguilhott Dalmarco E, Mendes De C\u00f3rdova CM, Fr\u00f6de TS (2011) Evidence of an anti-inflammatory effect of mycophenolate mofetil in a murine model of pleurisy. Exp Lung Res 37. https:\/\/doi.org\/10.3109\/01902148.2011.570416","DOI":"10.3109\/01902148.2011.570416"},{"key":"6820_CR63","doi-asserted-by":"publisher","unstructured":"Nelson VS, Jolink ATC, Amini SN, Zwaginga JJ, Netelenbos T, Semple JW et al (2021) Platelets in ITP: victims in charge of their own fate? Cells 10. https:\/\/doi.org\/10.3390\/cells10113235","DOI":"10.3390\/cells10113235"},{"key":"6820_CR64","doi-asserted-by":"publisher","unstructured":"Provan D, Semple JW (2022) Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine 76. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103820","DOI":"10.1016\/j.ebiom.2022.103820"},{"key":"6820_CR65","doi-asserted-by":"publisher","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood\u00a0 113. https:\/\/doi.org\/10.1182\/blood-2008-07-162503","DOI":"10.1182\/blood-2008-07-162503"},{"key":"6820_CR66","doi-asserted-by":"publisher","unstructured":"Onis\u00e2i M, Vl\u0103d\u0103reanu AM, Sp\u00eenu A, G\u0103man M, Bumbea H (2019) Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom J Intern Med 57. https:\/\/doi.org\/10.2478\/rjim-2019-0014","DOI":"10.2478\/rjim-2019-0014"},{"key":"6820_CR67","doi-asserted-by":"publisher","unstructured":"Miltiadous O, Hou M, Bussel JB (2020) Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 135. https:\/\/doi.org\/10.1182\/blood.2019003599","DOI":"10.1182\/blood.2019003599"},{"key":"6820_CR68","doi-asserted-by":"publisher","unstructured":"Psaila B, Bussel JB (2008) Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 143. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07275.x","DOI":"10.1111\/j.1365-2141.2008.07275.x"},{"key":"6820_CR69","doi-asserted-by":"publisher","unstructured":"Bylsma LC, Fryzek JP, Cetin K, Callaghan F, Bezold C, Mehta B et al (2019) Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting. Am J Hematol 94. https:\/\/doi.org\/10.1002\/ajh.25301","DOI":"10.1002\/ajh.25301"},{"key":"6820_CR70","doi-asserted-by":"publisher","unstructured":"Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3. https:\/\/doi.org\/10.1182\/bloodadvances.2019000812","DOI":"10.1182\/bloodadvances.2019000812"},{"key":"6820_CR71","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood-2010-08-302984","volume":"2011","author":"Neunert C, Lim W, Crowther MA, Cohen A, Solberg L. The American Society of Hematology","year":"2011","unstructured":"Neunert C, Lim W, Crowther MA, Cohen A, Solberg L. The American Society of Hematology (2011) evidence-based practice guideline for immune thrombocytopenia. Blood 2011:117. https:\/\/doi.org\/10.1182\/blood-2010-08-302984","journal-title":"Blood"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06820-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06820-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06820-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T06:11:58Z","timestamp":1706767918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06820-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6820"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06820-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}